NeuroSense Therapeutics EBIT

NeuroSense Therapeutics posts a EBIT of $-11M as of December 2025. That compares with $-9.9M in the prior-year period — down 11.9% year over year. That is above the sector sector average of $-69M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, NeuroSense Therapeutics's EBIT was $-9.9M. The latest reading is $-11M — a 11.9% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $-69M is typical. NeuroSense Therapeutics's $-11M is higher that level. That is roughly 83.9% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of NeuroSense Therapeutics's financial statement story. At $-11M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NRSN's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $-69M), and (3) consistency with growth and profitability. This page covers the first two; NeuroSense Therapeutics's other metric pages and overview cover the third.